Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting Aug 14, 2018
Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning Jul 17, 2018
Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients Jul 9, 2018
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients Jun 28, 2018
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial Jun 26, 2018
Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting Jun 25, 2018
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M Jun 13, 2018
Actinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, Belgium May 8, 2018
Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors May 1, 2018
Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development Apr 18, 2018
